Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dHER2+AS15
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
dHER2+AS15 is a cancer vaccine composed of a truncated recombinant HER2/neu peptide (dHER2) combined with the immunoadjuvant AS15. The vaccine is designed to stimulate an immune response against HER2-overexpressing tumor cells, primarily in breast cancer. The mechanism involves inducing both humoral and cellular immunity targeting the HER2 antigen, which is commonly overexpressed in certain types of breast cancer. The AS15 adjuvant system enhances the immunogenicity of the truncated HER2 protein by providing additional immune stimulation through its liposomal formulation containing three immunostimulatory components. Clinical studies have shown that this combination can induce durable antibody responses and has an acceptable safety profile in patients with early-stage or metastatic HER2-positive breast cancer who are resistant to trastuzumab[1][3][7]. The drug was initially developed by GSK.
- Other names
- dHER2 protein with AS15 adjuvantdHER-2 protein with AS15 adjuvantdHER 2 protein with AS15 adjuvant
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on dHER2+AS15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dHER2+AS15.